US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

26.34

+0.47001.82%

Post-market: 26.340.00000.00%16:20 EDT

Volume:226.52K

Turnover:5.88M

Market Cap:741.37M

PE:-11.26

High:26.44

Open:26.34

Low:24.86

Close:25.87

Loading ...

Overview Company News Filings

Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split

ACCESS Newswire

Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

Rakovina Therapeutics Unveils AI-Driven Cancer Therapy Advances at AACR 2025

Promising Imaging Data and Future Trials Support Buy Rating for Bicycle Therapeutics

Astria Therapeutics Initiated at Overweight by Cantor Fitzgerald

ProQR Therapeutics Initiated at Outperform by Evercore ISI Group

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

SpringWorks Therapeutics Cut to Hold From Buy by TD Cowen

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025

Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares

Cardiol Therapeutics Nominates Dr. Timothy Garnett to Board Amid Phase III Trial Progress

ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease

Bicycle Therapeutics Reveals Promising Imaging Data at AACR

Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025

Dianthus Therapeutics to Participate in Two Upcoming Investor Events

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LENZ/news?page=12"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":26.34,"timestamp":1746820800000,"preClose":25.87,"halted":0,"volume":226520,"hourTrading":{"tag":"盘后","latestPrice":26.34,"preClose":26.34,"latestTime":"16:20 EDT","volume":400,"amount":10536,"timestamp":1746822000343},"delay":0,"floatShares":11456571,"shares":28146154,"eps":-2.338654,"marketStatus":"Market Closed","change":0.47,"latestTime":"05-09 16:00:00 EDT","open":26.34,"high":26.44,"low":24.86,"amount":5880456.606978,"amplitude":0.061075,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.338654,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":25.87,"preHourTrading":{"tag":"盘前","latestPrice":26.3,"preClose":25.87,"latestTime":"09:29 EDT","volume":321,"amount":8435.569914,"timestamp":1746797398443},"postHourTrading":{"tag":"盘后","latestPrice":26.34,"preClose":26.34,"latestTime":"16:20 EDT","volume":400,"amount":10536,"timestamp":1746822000343},"volumeRatio":0.8674420486669012,"impliedVol":0.6531,"impliedVolPercentile":0.8182},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":11456571,"roa":"-17.75%","roe":"-24.47%","lyrEps":-2.338654,"volumeRatio":0.8674420486669012,"shares":28146154,"dividePrice":0,"high":26.44,"amplitude":0.061075,"preClose":25.87,"low":24.86,"week52Low":14.42,"pbRate":"3.86","week52High":38.93,"institutionHeld":0,"latestPrice":26.34,"eps":-2.338654,"divideRate":0,"volume":226520,"delay":0,"ttmEps":-2.338654,"open":26.34,"prevYearClose":28.87,"prevWeekClose":29.52,"prevMonthClose":28.515,"prevQuarterClose":25.71,"fiveDayClose":29.52,"twentyDayClose":18.54,"sixtyDayClose":24.84},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:12,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531479423","title":"Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2531479423","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531479423?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:00","pubTimestamp":1745956800,"startTime":"0","endTime":"0","summary":"Measure taken to Comply with Nasdaq Rule 5550 Regarding Minimum Bid Price. NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Protagenic Therapeutics, Inc.  , a leader in biopharmaceutical innovation, today announced that the Company's Board of Directors has approved a 1-for-14 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share  to be effective 12:01 a.m., Eastern Time, on May 5, 2025.The Company's Common Stock will continue to trade on the Nasdaq Capital Market LLC under the symbol \"PTIX\" following the reverse stock split, with a new CUSIP number of 74365N301. The Company expects its Common Stock to open for trading on a post split basis on Nasdaq as of the commencement of trading on May 5, 2025.Stockholders of record holding certificates holding pre-split shares of the Company's Common Stock will receive a l","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protagenic-therapeutics-effect-1-14-200000485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","PTIX","LENZ","PTIXW","BK4139"],"gpt_icon":0},{"id":"2531761270","title":"Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2531761270","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531761270?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:09","pubTimestamp":1745946540,"startTime":"0","endTime":"0","summary":"\"Zidesamtinib was specifically designed with the goal of addressing the combined medical needs of treating tumors that have developed resistance, treating brain metastases and avoiding off-target adverse events. Structural studies play a critical role in the development and optimization of novel therapeutics, particularly when aiming to solve for multiple, and at times competing, challenges. To date, structural studies for ROS1-positive cancers have been hindered by a lack of ROS1 G2032R crystal structures, despite G2032R being the most commonly occurring ROS1 resistance mutation,\" said first author Anupong Tangpeerachaikul, Ph.D., Director, Biology at Nuvalent. \"With this publication inMolecular Cancer Therapeutics, we are pleased to have shared what is, to our knowledge, the first structure of ROS1 G2032R, or any ROS1 mutation, offering a framework for understanding ROS1 TKI activity against these important drivers of disease progression. This structure further illustrates the intent","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nuvalent-announces-publication-molecular-cancer-170900549.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nuvalent-announces-publication-molecular-cancer-170900549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4539","LENZ","BK4135","CNS","NUVL","BK4139"],"gpt_icon":0},{"id":"2531775998","title":"Rakovina Therapeutics Unveils AI-Driven Cancer Therapy Advances at AACR 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531775998","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531775998?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:34","pubTimestamp":1745937279,"startTime":"0","endTime":"0","summary":"Rakovina Therapeutics Inc ( ($TSE:RKV) ) just unveiled an announcement. Rakovina Therapeutics Inc. presented promising preclinical data at the AACR...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rakovina-therapeutics-unveils-ai-driven-cancer-therapy-advances-at-aacr-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rakovina-therapeutics-unveils-ai-driven-cancer-therapy-advances-at-aacr-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2531737078","title":"Promising Imaging Data and Future Trials Support Buy Rating for Bicycle Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2531737078","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531737078?lang=en_us&edition=fundamental","pubTime":"2025-04-29 21:25","pubTimestamp":1745933131,"startTime":"0","endTime":"0","summary":"Analyst Ami Fadia of Needham maintained a Buy rating on Bicycle Therapeutics (BCYC – Research Report), reducing the price target to $29.00. Ami Fad...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-imaging-data-and-future-trials-support-buy-rating-for-bicycle-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-imaging-data-and-future-trials-support-buy-rating-for-bicycle-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2531731401","title":"Astria Therapeutics Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2531731401","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531731401?lang=en_us&edition=fundamental","pubTime":"2025-04-29 21:04","pubTimestamp":1745931840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATXS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2025 09:04 ET (13:04 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ATXS"],"gpt_icon":0},{"id":"2531736000","title":"ProQR Therapeutics Initiated at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2531736000","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531736000?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:49","pubTimestamp":1745930940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRQR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2025 08:49 ET (12:49 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRQR","LENZ"],"gpt_icon":0},{"id":"2531309387","title":"Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531309387","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531309387?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:45","pubTimestamp":1745930700,"startTime":"0","endTime":"0","summary":"SEATTLE, April 29, 2025  -- Atossa Therapeutics, Inc.  , a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today outlined a framework for a pioneering Phase 3 clinical study titled SMART 2.0. The proposed trial would investigate the potential of oral -endoxifen, a potent Selective Estrogen Receptor Modulator  for estrogen receptor inhibition, to significantly reduce interval breast cancer in women identified as high-risk through advanced mammographic screening techniques. The proposed SMART 2.0 study was presented at the American Association for Cancer Research  Annual Meeting and represents a future research program and potential partnership opportunity to advance this critical initiative for women at high risk of breast cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atossa-therapeutics-proposes-potentially-groundbreaking-124500381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4201","BK4585","ATOS","BK4007","BK4551","BK4588","BK4079","BK4139","Z","E","BK4548"],"gpt_icon":0},{"id":"2531736308","title":"SpringWorks Therapeutics Cut to Hold From Buy by TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2531736308","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531736308?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:41","pubTimestamp":1745930460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SWTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2025 08:41 ET (12:41 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","BK4007","BK4127","BK4585","BK4566","SWTX","COWN","LENZ","BK4139","TD"],"gpt_icon":0},{"id":"2531533147","title":"Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531533147","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531533147?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:30","pubTimestamp":1745929800,"startTime":"0","endTime":"0","summary":"Study showed engineered stem cell-derived therapy recruits key immune cells and slows tumor growth, supporting continued development of Ernexa’s advanced cancer pipeline. CAMBRIDGE, Mass., April 29, 2025  -- Ernexa Therapeutics , developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, presented noteworthy new data at the American Association for Cancer Research  Annual Meeting 2025 in Chicago on April 28. The study showed how engineered cells derived from stem cells could transform the treatment of ovarian cancer. The data revealed that these engineered cells, which release powerful immune-boosting cytokines, not only shrink tumors but also help the body’s immune system to attack the cancer more effectively.Ernexa Therapeutics  is developing innovative cell therapies for the treatment of advanced solid tumors and autoimmune disease. Ernexa’s core technology focuses on engineering induced pluripotent stem cells  and transforming them into induce","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ernexa-therapeutics-presented-promising-data-123000498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ERNA","LENZ","BK4007"],"gpt_icon":0},{"id":"2531050735","title":"Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531050735","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531050735?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:30","pubTimestamp":1745929800,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., April 29, 2025  -- Aligos Therapeutics, Inc. , a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets.Aligos Therapeutics, Inc.  is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis , and coronaviruses.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aligos-therapeutics-announce-1st-quarter-123000619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALGS","BK4505","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2531373368","title":"Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2531373368","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531373368?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:00","pubTimestamp":1745928000,"startTime":"0","endTime":"0","summary":"DUBLIN, Ireland and CHICAGO, April 29, 2025  -- Iterum Therapeutics plc  , a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of an aggregate of 5,555,556 ordinary shares  at a purchase price of $0.90 per ordinary share  in a registered direct offering . The closing of the Offering is expected to occur on or about April 30, 2025, subject to the satisfaction of customary closing conditions.H.C. Wainwright & Co. is acting as the exclusive placement agent for the Offering.This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unla","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/iterum-therapeutics-announces-5-million-120000189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ITRM","BK4139","LENZ"],"gpt_icon":0},{"id":"2531419787","title":"Cardiol Therapeutics Nominates Dr. Timothy Garnett to Board Amid Phase III Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2531419787","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531419787?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:58","pubTimestamp":1745927883,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Cardiol Therapeutics ( ($TSE:CRDL) ). Cardiol Therapeutics has nominated Dr. Timothy Garnett, a seasoned pharma...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cardiol-therapeutics-nominates-dr-timothy-garnett-to-board-amid-phase-iii-trial-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cardiol-therapeutics-nominates-dr-timothy-garnett-to-board-amid-phase-iii-trial-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4134","LU2065732104.USD","BK4139","III","BK4097","LENZ","BK4007","PRGS"],"gpt_icon":0},{"id":"2531801387","title":"ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2531801387","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531801387?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:57","pubTimestamp":1745927820,"startTime":"0","endTime":"0","summary":"Study supported by the Michael J. Fox Foundation through a grant awarded to ZyVersa and leading inflammasome experts at University of Miami Miller School of Medicine who conducted the study.Parkinson’s Disease  affects over 10 million people globally and is driven by inflammation leading to progressive neurodegeneration resulting in impaired mobility, cognitive decline, and other neurological symptoms.WESTON, Fla., April 29, 2025  -- ZyVersa Therapeutics, Inc. , a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces newly published data supporting the potential of its Inflammasome ASC Inhibitor IC 100 to slow the progression of Parkinson’s disease.Published in npj Parkinson's Disease, a peer-reviewed journal from Nature, the study presents groundbreaking findings from researchers at the University of Miami Miller School of Medicine. The research demonstrates that IC 100 blocks microglial inflammas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zyversa-therapeutics-announces-published-data-115700776.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","ZVSA","ASC","FSGS","LU1169590202.USD","BK4144","BK4139","PD","LU1169589451.USD","LENZ","BK4007"],"gpt_icon":0},{"id":"2531378719","title":"Bicycle Therapeutics Reveals Promising Imaging Data at AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2531378719","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531378719?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:51","pubTimestamp":1745927502,"startTime":"0","endTime":"0","summary":"Bicycle Therapeutics ( ($BCYC) ) has issued an update. On April 29, 2025, Bicycle Therapeutics announced additional human radiopharmaceutical imagi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bicycle-therapeutics-reveals-promising-imaging-data-at-aacr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bicycle-therapeutics-reveals-promising-imaging-data-at-aacr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2531784043","title":"Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2531784043","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531784043?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:27","pubTimestamp":1745926020,"startTime":"0","endTime":"0","summary":"Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience. Toronto, Ontario-- - Cardiol Therapeutics Inc.   , a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that pharmaceutical industry veteran Timothy J. Garnett, M.D., has been nominated to stand for election to the Company's Board of Directors at its 2025 Annual General Meeting of shareholders to be held on May 28, 2025.Cardiol Therapeutics Inc.   is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small molecule drug candidate, CardiolRx  oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cardiol-therapeutics-nominates-dr-timothy-112700107.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cardiol-therapeutics-nominates-dr-timothy-112700107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4139","LENZ","CRDL"],"gpt_icon":0},{"id":"2531314781","title":"Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2531314781","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531314781?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:02","pubTimestamp":1745924520,"startTime":"0","endTime":"0","summary":"MIAMI, April 29, 2025  -- Pasithea Therapeutics Corp.  , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1  and other MAPK pathway driven cancer indications, today announced the Company has completed enrollment and initial dosing of three subjects in Cohort 6 with 30 mg capsules of PAS-004.The ongoing Phase 1 clinical trial is a multi-center, open-label, dose escalation 3+3 study design to evaluate the safety, tolerability, pharmacokinetics , pharmacodynamics , and preliminary efficacy of PAS-004 in patients with MAPK pathway driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pasithea-therapeutics-announces-completion-enrollment-110200697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4157","KTTAW","BK4181","IE0031619046.USD","PD","BK4007","BK4218","CNS","LENZ","BK4135","LU1169590202.USD","BK4139","BK4023","AEIS","LU1169589451.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","KTTA","PK","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2531781941","title":"Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2531781941","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531781941?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:01","pubTimestamp":1745924460,"startTime":"0","endTime":"0","summary":"European Commission converts conditional approval of FILSPARI into standard marketing authorization for the treatment of IgAN. EU approval is based on the complete data set from the Phase 3 PROTECT Study. The UK’s MHRA also converts the conditional approval of FILSPARI to standard approval. The European Commission's decision follows the Committee for Medicinal Products for Human Use  recommendation from February 2025 to convert the CMA to standard MA. The approval is based on a comprehensive clinical data set, including positive confirmatory results from the pivotal Phase 3 PROTECT Study demonstrating that FILSPARI significantly slowed kidney function decline over two years compared to irbesartan.In the UK, the Medicines and Healthcare products Regulatory Agency  converted the conditional FILSPARI approval to standard approval as of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/travere-therapeutics-csl-vifor-announce-110100458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2106854487.HKD","IE0004086264.USD","TVTX","LU0345769128.USD","LU0820561818.USD","LU2543165471.USD","LU2054465674.USD","LU1670627923.USD","LU2462157665.USD","CHMP","ETAR","LU0494093205.USD","LU0056508442.USD","LU0289941410.SGD","LU0109392836.USD","IE0004445239.USD","GB00BDT5M118.USD","BK4207","LU0823421416.USD","BK4106","CMA","LU0353189763.USD","LU0964807845.USD","LU1084165304.USD","IE00B775H168.HKD","SGXZ51526630.SGD","LU0390134368.USD","LU0107464264.USD","LU1551013425.SGD","CSL","BK4548","LU0256863811.USD","SGXZ99366536.SGD","LU0985320562.USD","LU2764263039.SGD","LU0011850046.USD","LU0053666078.USD","LU0316494557.USD","BK4566","BK4581","IE0004091025.USD","SMP","BK4589","BK4585","ARB","LENZ","LU1983260115.SGD","MA","LU0109391861.USD"],"gpt_icon":0},{"id":"2531866377","title":"Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531866377","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531866377?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:00","pubTimestamp":1745924400,"startTime":"0","endTime":"0","summary":"Data are representative of 12 patients with various solid tumors imaged with an early BRC molecule targeting MT1-MMP. Initial human imaging data for second BRC molecule targeting EphA2 expected in 2H 2025. The German Cancer Consortium , part of a cooperative network with the German Cancer Research Center , will present human imaging data conducted with an early BRC molecule targeting MT1-MMP. Imaging was performed in a 65-year-old male diagnosed with advanced pulmonary adenocarcinoma, the most common type of non-small cell lung cancer, and an 84-year-old female diagnosed with invasive ductal breast cancer and high-grade urothelial  cancer.The 65-year-old male patient with advanced pulmonary adenocarcinoma underwent fluorine-18-labelled FDG-PET/CT imaging and two weeks later underwent MT1-MMP-PET/CT imaging up to one hour post injection of the gallium-68-labelled BRC tracer. As presented at a previous medical meeting, the MT1-MMP-PET scan demonstrated BRC tracer uptake in the primary tu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bicycle-therapeutics-announces-presentation-additional-110000522.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IHC","LENZ","BK4117","BK4162","AFG","BCYC","BK4139","BK4107"],"gpt_icon":0},{"id":"2531786982","title":"Dianthus Therapeutics to Participate in Two Upcoming Investor Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2531786982","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531786982?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:00","pubTimestamp":1745924400,"startTime":"0","endTime":"0","summary":"NEW YORK and WALTHAM, Mass., April 29, 2025  -- Dianthus Therapeutics, Inc. , a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation at two upcoming investor events.Baird Biotech Discovery Series - Marino Garcia, Chief Executive Officer, will participate in a fireside chat webcast on Tuesday, May 6 at 1:30 p.m. EDT.Bank of America 2025 Health Care Conference – Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, May 14 at 5:35 p.m. EDT / 2:35 p.m. PDT and will host one-on-one meetings with investors.Webcasts of these presentations may be accessed under “News and Events” in the Investorssection of the Dianthus Therapeutics website.To learn more, please visit www.dianthustx.com and follow us on LinkedIn.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dianthus-therapeutics-participate-two-upcoming-110000069.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","DNTH","BK4007","BK4139"],"gpt_icon":0},{"id":"2531781612","title":"Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2531781612","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531781612?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:00","pubTimestamp":1745924400,"startTime":"0","endTime":"0","summary":"MENLO PARK, Calif., April 29, 2025  -- Oruka Therapeutics, Inc.  , a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced a presentation at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13th, 2025, at 3:55 PM PT.Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more inform","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oruka-therapeutics-present-bank-america-110000866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1880398471.USD","IE00BLSP4452.SGD","LU0106831901.USD","LU0683600562.USD","LU0314106906.USD","LU0130102774.USD","LU0320765646.SGD","LU1880398554.USD","BK4139","LU1496350171.SGD","BK4581","BK4504","IE00BZ1G4Q59.USD","LU0130103400.USD","IE0002270589.USD","LU2129689514.USD","LU0306806265.USD","LU1201861249.SGD","LU0321505439.SGD","LU0052756011.USD","BAC","LU0256863902.USD","LU0868494617.USD","IE00B19Z3B42.SGD","LU0971096721.USD","LU0128525689.USD","BK4553","LU0320765489.SGD","IE00B19Z3581.USD","BK4207","BK4585","LU1363072403.SGD","LU1894683348.USD","LU0310800965.SGD","IE00B7SZLL34.SGD","LU0098860793.USD","LU0477156797.USD","LU0070302665.USD","LU0149725797.USD","LU0321505868.SGD","LU0417517546.SGD","LU1201861165.SGD","LU2129689431.USD","LU2129689605.HKD","LU1791807156.HKD","LENZ","LU0648001328.SGD","IE00BFXG1179.USD","BK4534","ORKA"],"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":12,"totalSize":287,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53},{"market":"US","date":"2024-03-22","symbol":"LENZ","defaultRemindTime":1711114200000,"type":"split","dateTimestamp":1711080000000,"forFactor":7,"toFactor":1,"ratio":7},{"date":"2024-03-22","symbol":"LENZ","amount":1.03,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-18","name":"Therapeutics","recordDate":"2024-03-21","payableDate":"2024-03-18","currency":"USD","dateTimestamp":1711080000000,"payDate":"2024-03-21"},{"market":"US","date":"2021-08-12","symbol":"LENZ","fiscalQuarterEnding":"2021/06","expectedEps":-1.11,"name":null,"time":"","type":"earning","dateTimestamp":1628740800000,"reportTimeType":"","actualEps":-3.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1742270400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2025-05-09","current":-15.25222,"percent":0.091255,"low":-16.900596,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"high":-5.069183,"avg":-10.27698,"sd":3.318099,"marketCap":728141003},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003}],"updateTime":1746875046385}}}